Stable Angina Pectoris Clinical Trial
Official title:
BioMatrix NeoFlex Post Marketing Surveillance in Validate (the BASIC VALIDATE) Registry)
BASIC VALIDATE is a coronary stent registry to obtain clinical follow-up information from 2000 patients treated with CE-marked stent (BioMatrix Flex™, Biosensors International) with follow-up of endpoints via the Swedish angiography and angioplasty registry (SCAAR - part of the national SWEDEHEART registry).
Purpose of the study The purpose of this registry is to capture clinical data of the BioMatrix NeoFlex™ stent (an improved version of the delivery system of the Biolimus A9™-eluting BioMatrix Flex stent) in relation to safety and effectiveness in the VALIDATE SWEDEHEART trial and in a group of patients not taking part in VALIDATE SWEDEHEART in addition to a group of patients with stable angina pectoris. Clinical relevance The European Union has a focus on and encourages the conductance of post marketing surveillance studies of medical devices 3. This focus should be seen in the light of limitations to clinical data available in the pre-market phase owing to duration of pre-market clinical investigations, the number of subjects and investigators involved in an investigation, the relative heterogeneity of subjects and investigators and the controlled setting of a clinical investigation versus the full range of clinical conditions encountered in general medical practice. The extent of the data that can be gathered in the pre-market phase does not necessarily enable detection of rare complications or problems that only become apparent after widespread or long term use of the device. Because the study device (BioMatrix NeoFlex™) is a CE-marked updated version of the BioMatrix Flex stent it is important to document that the assumed improvements in delivery design also reflect improvements in a clinical setting. Patients and methods Patients A total of 6000 patients will be included in the VALIDATE SWEDEHEART trial. 3000 STEMI and 3000 NSTEMI. The ambition is that approximately 1000 of these patients are also included in the BASIC VALIDATE stent registry. In addition, and in order to achieve post-market information from the entire spectrum of PCI, another 1000 patients with stable angina pectoris, STEMI or NSTEMI will be included in the registry at VALIDATE SWEDEHEART centers but unrelated to the VALIDATE SWEDEHEART trial. Treatment strategy During the index procedure, only BioMatrix NeoFlex™ stents will be implanted. The investigator will choose the appropriate length and diameter of the stents to be implanted by visual estimate. The choice of the length of the stent should ensure complete coverage of the lesion. In case of insufficient stent expansion, post-dilatation is highly recommended. In the event that a staged procedure is expected or planned it is recommended NOT to include the patient in the BASIC VALIDATE registry because the nature of follow-up of patients (registry only) means that staged procedures will be classified as events ("repeat" revascularizations). After the index PCI, lifelong acetylsalicylic acid in a dose of 75-160 mg per day will be prescribed. Duration and choice of post-PCI P2Y12 inhibition is left to the discretion of the treating physician. Endpoints Primary endpoint A composite of time to death, myocardial infarction, stent thrombosis or repeat revascularization at 12 months. Secondary endpoints - Time to death at 1, 3 and 5 years. - Time to myocardial infarction at 1, 3 and 5 years. - Time to stent thrombosis at 1, 3 and 5 years. - Time to repeat revascularization at 1, 3 and 5 years. - Analysis of the primary endpoint in the NSTEMI and STEMI groups separately. All endpoint results will be compared to matched populations of patients treated with drug-eluting coronary stents as documented in the SCAAR/SWEDEHEART registries. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01257282 -
Prevalence and Prognostic Value of Unrecognized Myocardial Injury in Stable Coronary Artery Disease (PUMI)
|
N/A | |
Completed |
NCT02294942 -
Extended-Release RANCAD in the Patients With Stable Angina Pectoris
|
Phase 3 | |
Completed |
NCT02029118 -
Acupoint Application in Patients With Stable Angina Pectoris (AASAP)
|
Early Phase 1 | |
Completed |
NCT00763464 -
Coronary Artery Disease (CAD) in Postmenopausal Women
|
N/A | |
Recruiting |
NCT02328898 -
Randomized "All-comer" Evaluation of a Permanent Polymer Resolute Integrity Stent Versus a Polymer Free Cre8 Stent
|
Phase 4 | |
Completed |
NCT02339454 -
Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris
|
Phase 3 | |
Completed |
NCT01502943 -
Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index
|
Phase 4 | |
Terminated |
NCT00638326 -
Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity
|
Phase 3 | |
Completed |
NCT01632371 -
Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4
|
Phase 4 | |
Completed |
NCT01363661 -
Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
|
Phase 4 | |
Completed |
NCT01293097 -
Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI
|
Phase 4 | |
Completed |
NCT02747329 -
A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT
|
N/A | |
Recruiting |
NCT05347069 -
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
|
Phase 4 | |
Recruiting |
NCT04938661 -
Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE)
|
N/A | |
Not yet recruiting |
NCT03155971 -
PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial)
|
N/A | |
Active, not recruiting |
NCT02285322 -
Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study
|
N/A | |
Active, not recruiting |
NCT02062021 -
Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease
|
N/A | |
Active, not recruiting |
NCT01947361 -
Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)
|
N/A | |
Active, not recruiting |
NCT01937065 -
Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study
|
N/A | |
Completed |
NCT01669382 -
Angio-Seal® vs. Exo-Seal® for Closure of Arterial Puncture Sites
|
Phase 3 |